Literature DB >> 17902092

Limited additional value of positron emission tomography in staging oesophageal cancer.

H L van Westreenen1, M Westerterp, G W Sloof, H Groen, P M M Bossuyt, P L Jager, E F Comans, H M van Dullemen, P Fockens, J Stoker, E J van der Jagt, J J B van Lanschot, J T M Plukker.   

Abstract

BACKGROUND: The detection of distant metastases in patients with oesophageal cancer may be improved with [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET), preventing unnecessary surgical explorations. The aim of this study was to assess the additional value of FDG-PET after a state-of-the-art preoperative staging protocol.
METHODS: All patients in this prospective cohort study were staged with multidetector computed tomography, endoscopic ultrasonography and external ultrasonography of the neck, both combined with selective fine-needle aspiration cytology. Patients considered eligible for curative surgery after these investigations underwent FDG-PET.
RESULTS: FDG-PET revealed suspicious hot spots in 30 (15.1 per cent) of 199 patients. Metastases were confirmed in eight (4.0 per cent). In six of these, distant metastases were confirmed before surgery, but exploratory surgery was necessary for histological confirmation in the other two. All eight upstaged patients had clinical stage III-IV disease before FDG-PET (6.6 per cent of 122 with stage III-IV disease). In seven patients (3.5 per cent) hot spots appeared to be synchronous neoplasms, mainly colonic polyps. However, those in the remaining 15 (7.5 per cent) were false positive, leading to unnecessary additional investigations.
CONCLUSION: FDG-PET improves the selection of patients with oesophageal cancer for potentially curative surgery, especially in stages III-IV. However, the diagnostic benefit is limited after state-of-the-art staging, and so broad implementation in daily clinical practice is questionable. Copyright (c) 2007 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902092     DOI: 10.1002/bjs.5708

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  19 in total

1.  The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management.

Authors:  Soumil Vyas; Sheraz R Markar; Lydia Iordanidou; Samantha Read; David Stoker; Majid Hashemi; Ian Mitchell; Mark Winslet; Jamshed Bomanji
Journal:  J Gastrointest Surg       Date:  2011-10-01       Impact factor: 3.452

Review 2.  Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.

Authors:  P M Price; M M Green
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

3.  Oesophageal cancer: can imaging improve its assessment?

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

4.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

5.  Positron emission tomography-computed tomography in oesophageal cancer staging: a tailored approach.

Authors:  David M Bunting; Wesley W Lai; Richard G Berrisford; Tim J Wheatley; Brent Drake; Grant Sanders
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

6.  FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer.

Authors:  Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Kazuya Takeda; Yojiro Ishikawa; Noriyoshi Takahashi; Noriyuki Kadoya; Haruo Matsushita
Journal:  Int J Clin Oncol       Date:  2019-03-12       Impact factor: 3.402

7.  Positron Emission Tomography's Utility in Esophageal Cancer Management.

Authors:  Shane Hopkins; Gary Y Yang
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

Review 8.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

Review 9.  Oesophageal cancer--an overview.

Authors:  Michael Schweigert; Attila Dubecz; Hubert J Stein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

10.  The early use of PET-CT alters the management of patients with esophageal cancer.

Authors:  R N Williams; S S Ubhi; C D Sutton; A L Thomas; J J Entwisle; D J Bowrey
Journal:  J Gastrointest Surg       Date:  2009-01-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.